Retractable Technologies, Inc.
RVP Healthcare Medical Instruments & Supplies
Retractable Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.3 million, up 15.8% from fiscal 2024. In the quarter to June 2026, revenue fell 31.1%, EPS was flat, free cash flow grew 56.7% and total debt fell 32.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow RVP
Retractable Technologies, Inc. (RVP) P/E ratio
Retractable Technologies, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 82.0× (June 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 11.5× | 173.02% |
| FY2021 | 4.2× | (71.90%) |
| FY2020 | 14.9× | (20.28%) |
| FY2019 | 18.8× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| FEMY Femasys Inc. compare | n/m |
| RVP Retractable Technologies, Inc. | n/m |
| MLSS Milestone Scientific, Inc. compare | n/m |
| HBIO Harvard Bioscience, Inc. compare | n/m |
| NXGL NexGel, Inc. compare | n/m |
| BNGO Bionano Genomics, Inc. compare | n/m |
| NEPH Nephros Inc. compare | 23.4× |
| RGNT Regentis Biomaterials Ltd. compare | — |
| CUPR Cuprina Holdings (Cayman) Limited compare | — |
| Medical Instruments & Supplies industry median | 33.8× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)